Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Allovir, Inc. (ALVR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "AlloVir Reports Second Quarter 2023 Financial Results"
05/04/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"AlloVir Reports First Quarter 2023 Financial Results"
11/03/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
11/05/2021 8-K Quarterly results
Docs: "AlloVir Reports Third Quarter 2021 Financial Results"
08/06/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : August 6, 2021 ALLOVIR, INC. Delaware 001-39409 83-1971007 AlloVir, Inc. 139 Main Street, Suite 500 Cambridge, Massachusetts 02142 433-2605 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant t...",
"AlloVir Reports Second Quarter 2021 Financial Results"
05/06/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 10, 2020 ALLOVIR, INC. Delaware 001-39409 83-1971007 AlloVir, Inc. 139 Main Street, Suite 500 Cambridge, Massachusetts 02142 433-2605 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuan...",
"AlloVir Reports Third Quarter 2020 Financial Results"
09/02/2020 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy